A study and Exploratory Clinical trial on chronological changes of the Iomazenil SPECT in coping with Higher brain dysfunction after cerebral trauma

A study and Exploratory Clinical trial on chronological changes of the Iomazenil SPECT in coping with Higher brain dysfunction after cerebral trauma - A study and Exploratory Clinical trial on chronological changes of the Iomazenil SPECT in coping with Higher brain dysfunction after cerebral trauma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021732

Enrollment

Registered

2016-04-22

Start date

2016-04-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Higher brain dysfunction following traumatic brain injury

Interventions

Diagnosis by Iomazenil SPECT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who present with higher brain dysfunction by cerebral trauma (TBI) who are are visiting a hospital for treatment or the hospitalized patient in a Hokkaido University Hospital Rehabilitation Medicine (1) The Age is more than 15-year-old patient at the agreement acquisition. The sex does not matter. (2) The patients without the contraindication for the MRI and SPECT as a preoperative routine imaging study (3) The patients that a document agreement by the free will of the patients or legal representative was obtained after having received enough explanation and understanding in participation of this study (4) The patients who are more than 2 months after injury (5) The patients without the contraindication for the Standard therapies method including the rehabilitation

Exclusion criteria

Exclusion criteria: (1) The patients who cannot discontinue benzodiazepine drugs for one week (2) The patients who cannot conduct various tests such as nerve psychological tests (3) The patients with a history of other mental disorder and neurologic disease (4) The patient with serious liver dysfunction, serious renal dysfunction, or dysuria (5) In addition, the patient whom a study person in charge judged to be inadequate as subjects

Design outcomes

Primary

Measure	Time frame
<Efficacy> Presence or absence of changes of IMZ-SPECT one year later	—

Countries

Japan

Contacts

Public ContactTohru Shiga

Hokkaido University, Graduate School of Medicine Department of Nuclear Medicine

kakui-s@med.hokudai.ac.jp011-706-5152

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026